Related Experiment Video
Updated: Nov 30, 2025
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
COVID-19-Related Intracerebral Hemorrhage
Valentin Pavlov1,2, Ozal Beylerli1, Ilgiz Gareev1
1Central Research Laboratory, Bashkir State Medical University, Ufa, Russia.
Insights
Intracerebral hemorrhage (ICH), a severe brain bleed, can be a complication of COVID-19. This study reports three cases of ICH in patients with COVID-19, exploring potential causes.
Area of Science:
- Neurology
- Infectious Diseases
- Vascular Medicine
Background:
- Intracerebral hemorrhage (ICH) is a severe neurological condition with high mortality and morbidity.
- ICH is frequently linked to advanced age and comorbidities like hypertension and diabetes.
- The COVID-19 pandemic has presented with diverse neurological complications, including ICH.
Observation:
- This study observed three cases (0.25%) of ICH among 1200 COVID-19 admissions.
- The cases occurred between May 1 and August 4, 2020.
Findings:
- COVID-19 may contribute to hemorrhagic stroke through mechanisms such as ACE2 receptor depletion and heightened immune responses.
- Reported cases highlight a potential link between SARS-CoV-2 infection and the development of ICH.
Implications:
- Understanding the pathophysiology of COVID-19-associated ICH is crucial for clinical management.
- Further research is needed to elucidate the precise mechanisms and guide treatment strategies for neurological complications of COVID-19.
Abstract:
Intracerebral hemorrhage (ICH) is a common and severe neurological disorder and is associated with high rates of mortality and morbidity. ICH is associated with old age and underlying conditions such as hypertension and diabetes mellitus. The COVID-19 pandemic is associated with neurological symptoms and complications including ICH. For instance, the mechanisms by which COVID-19 may contribute to hemorrhagic stroke may include both depletion of angiotensin converting enzyme 2 (ACE2) receptor and overactive immune response. In this study, we herein report three patients (0.25%) out of 1200 admissions with COVID-19 to our center between 1 May and August 4, 2020, who developed ICH. In addition, we will briefly discuss the possible pathophysiological mechanisms of COVID-19 infection in patients with ICH.
